A potentially monumental lawsuit that could stop the sales of abortion drugs nation-wide and save hundreds of thousands of lives is scheduled for a hearing Wednesday in Texas.
The abortion drug mifepristone is used for more than half of all abortions in the U.S. every year, or hundreds of thousands of unborn babies, according to the Guttmacher Institute.
But a new lawsuit, filed by a group of doctors with the Alliance for Hippocratic Medicine, challenges the U.S. Food and Drug Administration’s approval and later expansion of the deadly drug under the Clinton, Obama and Biden administrations. Represented by the Alliance Defending Freedom, the doctors point to evidence that the FDA ignored safety problems and failed to properly study the risks of mifepristone.
The case has abortion activists alarmed, worrying that U.S. Judge Matthew Kacsmaryk of the Northern District of Texas could block approval of the drug and make it unavailable to hundreds of thousands of women nation-wide. Over the weekend, Kacsmaryk, who was appointed by President Donald Trump, said the court has received numerous threats, including death threats in response to the case.
Click here to sign up for pro-life news alerts from LifeNews.com
His ruling potentially could save hundreds of thousands of unborn babies’ lives.
First approved under the Clinton administration, mifepristone is used to abort unborn babies up to about 10 weeks of pregnancy – although some abortionists use it later. It works by blocking the hormone progesterone and basically starving the unborn baby to death. Typically, abortion groups also prescribe a second drug, misoprostol, to induce labor and expel the baby’s body.
Since the overturning of Roe v. Wade, the pro-abortion movement has been pushing abortion drugs even more heavily, and some groups send the drugs to women in pro-life states illegally.
Meanwhile, the Biden administration has been trying to expand the life-destroying drugs even further, first by allowing abortion drugs to be sold through the mail without any direct medical supervision, and, more recently, by allowing pharmacies like Walgreens, CVS and RiteAid to sell them.
In California, public colleges and universities also are required to provide abortion drugs for free on campus, and other Democrat-run states are considering similar mandates.
But a ruling by the federal judge potentially could change that.
Here’s more from National Review:
It is unclear if Kacsmaryk will issue a ruling the day of the hearing or at a later date. If he rules in the plaintiffs’ favor, it could mean that the FDA would be forced to withdraw its approval for the abortion-pill regimen, or safeguards could be reimposed on the use of the pills for abortions.
The Biden administration has vowed a legal challenge if Kacsmaryk’s ruling restricts the use of abortion pills. If a ruling in the plaintiffs’ favor was upheld on appeal, it would likely make it harder for women to get abortions even in states where it is legal.
Along with millions of unborn babies’ deaths, the FDA has linked mifepristone to at least 28 women’s deaths and 4,000 serious complications. However, under President Barack Obama, the FDA stopped requiring that non-fatal complications from mifepristone be reported. So the numbers almost certainly are much higher.
Studies indicate the risks of the abortion drug are more common than what abortion activists often claim, with as many as one in 17 women requiring hospital treatment. A recent study by the Charlotte Lozier Institute found that the rate of abortion-related emergency room visits by women taking the abortion drug increased more than 500 percent between 2002 and 2015.
Another new study from the University of Toronto, “Short-Term Adverse Outcomes After Mifepristone–Misoprostol Versus Procedural Induced Abortion,” published in the Annals of Internal Medicine, found that one in ten women who took the abortion pill had to go to the emergency room, according to Pregnancy Help News.
The post Huge Abortion Pill Case Could be Bigger Than Dobbs, Save Millions of Babies From Abortion Nationwide appeared first on LifeNews.com.